Abstract: The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A method of semantic searching. The method may include receiving a first search query, obtaining a disambiguation term for semantically disambiguating the first search query, and creating, with a processor, a second search query based at least in part on the first search query and the disambiguation term. The method may also include at least one of outputting search results obtained from a search conducted based at least in part on the second search query and sending the second search query to a search service for outputting search results.

Abstract: A method of semantic searching. The method may include receiving a first search query, obtaining a disambiguation term for semantically disambiguating the first search query, and creating, with a processor, a second search query based at least in part on the first search query and the disambiguation term. The method may also include at least one of outputting search results obtained from a search conducted based at least in part on the second search query and sending the second search query to a search service for outputting search results.

Abstract: The present magnetically bound media with reattachable pages exemplarily comprise a magnetic binding, one or more reattachable pages, and one or more conductive metals attached to the pages and magnetically attracted to the magnetic binding. Thus, a user of the magnetically bound media may disengage one or more of the pages from the magnetic binding and reintegrate those pages into the magnetic binding in any order. This allows for customization of information presentation, sequence, and selection. The small size of the magnetic binding also affords a smaller minimum apparatus size and a quicker means with which to remove, rearrange, and reintegrate pages. Furthermore, the magnetic binding permits pages to be secured in a more professionally presentable manner without punched holes. In an exemplary embodiment, the magnetic binding is a cylindrical or a prismatic, rectangular neodymium or samarium alloy secured within the bound media by a magnet cover or clasp.

Abstract: Processing changes to a document is disclosed. An indication that changes, if any, affecting the document or a portion thereof are to be reviewed is received. The document comprises one or more segments each of which is configured to be generated automatically based at least in part on data from a data source associated with the segment. An ability to review a subset of changes affecting the document is provided, where the changes in the subset affect particular segment(s) of the document.

Abstract: Processing changes to a document is disclosed. An indication that changes, if any, affecting the document or a portion thereof are to be reviewed is received. The document comprises one or more segments each of which is configured to be generated automatically based at least in part on data from a data source associated with the segment. An ability to review a subset of changes affecting the document is provided, where the changes in the subset affect particular segment(s) of the document.

Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Embodiments of methods, apparatuses, devices and systems associated with document generation are disclosed. For example, methods, apparatuses, devices, and systems associated with formatting content for display are disclosed. Including method apparatuses, devices, and systems to read a data file and a template file, create one or more sub-assemblies based at least in part on said template file and/or said data file; and execute one or more tags in said template file to populate said one or more sub-assemblies with data from said data file.

Abstract: A method of semantic searching. The method may include receiving a first search query, obtaining a disambiguation term for semantically disambiguating the first search query, and creating, with a processor, a second search query based at least in part on the first search query and the disambiguation term. The method may also include at least one of outputting search results obtained from a search conducted based at least in part on the second search query and sending the second search query to a search service for outputting search results.

Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R?, R3, R3?, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Abstract: The present invention relates to tripeptide compounds, compositions containing such compounds and methods for using such compounds for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Abstract: The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals or treat hepatitis C virus (HCV) infection.